BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Xenetic Biosciences  

Greener House
66-68 Haymarket
  London  SW1Y 4RF  United Kingdom
Phone: 44-0-20-3021-1500 Fax: 44-0-20-3021-1511


SEARCH JOBS










 Company News
Xenetic Biosciences Announces Board Change 4/22/2015 8:18:57 AM
Xenetic Biosciences To Hold Business Update Conference Call January 20th 1/19/2015 11:12:25 AM
Xenetic Biosciences Completes Enrollment Of Second Cohort In Phase 2a Study With Erepoxen® For Anemia; Hemoglobin Levels Rise Into Therapeutic Range Over Time 12/19/2014 11:18:51 AM
Xenetic Biosciences CEO Delivers “2014 – The Year In Review” Update To Investors And Stakeholders 12/18/2014 9:28:47 AM
Xenetic Biosciences Announces OncoHist™ Preclinical Data To Be Featured In A Poster Presentation At The American Society of Hematology Annual Meeting 12/4/2014 9:58:06 AM
Xenetic Biosciences Partner Completes Dosing Of Second Cohort In Phase 2a Study Of Erepoxen® In Patients With Chronic Kidney Disease On Dialysis 12/2/2014 11:35:23 AM
Xenetic Biosciences Provides Update On Substantial Patent Grants And Allowances In U.S. and Worldwide 11/25/2014 9:04:16 AM
Xenetic Biosciences Partner Completes First Patient Cohort In Phase 2 Study With MyeloXen™ For Multiple Sclerosis 11/21/2014 8:29:57 AM
Xenetic Biosciences To Hold Business Update Conference Call September 23 At 6:00 A.M. Eastern Time 9/23/2014 9:42:56 AM
Xenetic Biosciences To Hold Business Update Conference Call September 23 At 6:00 A.M. Eastern Time 9/22/2014 10:13:07 AM
123